Settlement

A judge has signed off on a $230 million settlement of a class action on behalf of thousands of junior doctors who allege they were systemically underpaid by the NSW government.

A $13.5 million settlement has been reached in a Gadens-led class action against former Quintis director Frank Wilson, and the funder of a rival class action is preparing to seek a chunk of the sum in what a judge has called a “most unusual circumstance”.

Transurban has settled a lawsuit by the former head of legal for its West Gate Tunnel project alleging she was made redundant after complaining about a "culture of fear and intimidation on the project".

A judge has signed off on a $23.1 million cut for funder Augusta of a $100 million settlement in a class action against Colonial First State, which he previously called "strange" and said may not reflect the risk the funder shared with Slater & Gordon in running the case.

A Gadens-led class action against former Quintis director Frank Wilson has settled, but a second class action filed by a rival firm has flagged a potential claim on the settlement funds over a cause of action said to have been “picked up parasitically”. 

In the first-ever settlement approval hearing involving a group costs order, a contradictor has argued that Slater & Gordon should have provided the court with more information on legal costs and internal rate of return as part of its bid for a $12.8 million contingency fee.

The judge considering a $272 million settlement in class actions against Uber will appoint a pair of contradictors to advise her on the hundreds of objections lobbed against the agreement.

US footwear giant Crocs has reached a settlement with Mosaic Brands in a lawsuit accusing the Rivers owner of settling shoes that "flagrantly" copy the look of its unique 13-hole slip-on foam clogs.

Group members in a class action against ANZ over credit card interest charges that settled for $57.5 million are expected to take home at least 60 per cent of the settlement sum after legal fees and a funder's commission are deducted.

Generic drug maker Mayne Pharma has resolved a shareholder class action centred on disclosures connected to price-fixing claims by US regulators.